Medical research firm Recardio has halted clinical trials of its heart drug in the UK, citing uncertainty over Brexit. The US company was due to conduct trials of dutogliptin on patients in Clydebank, Exeter and Leeds, but has now suspended all its activities in the UK. " Recardio's founder and president, Dr Roman Schenk, told the BBC he did not want to comment on UK politics. Recardio faces a "significant risk" from Brexit and "unresolved" issues with the European Medicines Agency, the company reportedly wrote in an email to its research team. A spokesperson for the Department of Health said that it had not yet received any official notification about the UK government's decision to suspend Dutogliptin.
Medical research firm Recardio has halted clinical trials of its heart drug in the UK, citing uncertainty over Brexit. The US company was due to conduct trials of dutogliptin on patients in Clydebank, Exeter and Leeds, but has now suspended all its activities in the UK. Recardio faces a "significant risk" from Brexit and "unresolved" issues with the European Medicines Agency, the company reportedly wrote in an email to its research team. A spokesperson for the Department of Health said that it had not yet received any official notification about the UK government's decision to suspend Dutogliptin.